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Abstract
Damage to limbal stem cells as a result of injury or disease can lead to limbal stem cell
deficiency (LSCD). This disease is characterized by decreased vision that is often
painful and may progress to blindness. Clinical features include inflammation,
neovascularization, and persistent cornea epithelial defects. Successful strategies for
treatment involve transplantation of grafts harvested from the limbus of the alternate
healthy eye, called conjunctival-limbal autograft (CLAU) and transplantation of limbal
cell sheets cultured from limbal biopsies, termed cultured limbal epithelial transplan-
tation (CLET). In 2012, Sangwan and colleagues presented simple limbal epithelial
transplantation (SLET), a novel transplantation technique that combines the benefits
of CLAU and CLET and avoids the challenges associated with both. In SLET a small
biopsy from the limbus of the healthy eye is divided and distributed over human
amniotic membrane, which is placed on the affected cornea. Outgrowth occurs from
each small explant and a complete corneal epithelium is typically formed within
2 weeks. Advantages of SLET include reduced risk of iatrogenic LSCD occurring in
the healthy cornea at harvest; direct transfer circumventing the need for cell culture;
and the opportunity to perform biopsy harvest and transplantation in one operation.
Success so far using SLET is comparable with CLAU and CLET. Of note, 336 of
404 (83%) operations using SLET resulted in restoration of the corneal epithelium,
whereas visual acuity improved in 258 of the 373 (69%) reported cases. This review
summarizes the results of 31 studies published on SLET since 2012. Progress, advan-
tages, challenges, and suggestions for future studies are presented.
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1 | INTRODUCTION
The corneal epithelium is renewed by stem cells located in specialized
niches in the limbus at the cornea-conjunctiva junction. Loss or dam-
age to the limbal stem cell pool can lead to limbal stem cell deficiency
(LSCD), where homeostatic maintenance of the corneal epithelium is
Abbreviations: alloSLET, allogenic SLET; AM, amniotic membrane; AMT, amniotic membrane
transfer; CLAU, corneal limbal autograft; CLET, cultured limbal epithelial transplantation;
COMET, cultured oral mucosal epithelial transplantation; lr-CLAL, living-related conjunctival
limbal allograft; KLAL, keratolimbal allograft; LSCD, limbal stem cell deficiency; MMP, mucous
membrane phemigoid; OSSN, ocular surface squamous neoplasia; PK, penetrating
keratoplasty; SLET, simple limbal epithelial transplantation; SOMET, simple oral mucosal
epithelial transplantation; VEGF, vascular endothelial growth factor; ΔNp63α+, delta p63
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compromised, leading to ingrowth of the conjunctiva. Etiology
includes autoimmune diseases (Steven-Johnson syndrome), infections
(trachoma), contact lens wear, and thermal/alkali burns. LSCD may be
partial or total depending on the extent of the damage.1 Con-
junctivalization is pathogenic for LSCD and is frequently accompanied
by inflammation, neovascularization, persistent epithelial defects, and
scarring resulting in decreased vision or blindness.
Several surgical and stem cell-based treatments for LSCD have been
developed over the last decades.1 Simple limbal epithelial transplantation
(SLET) is a new treatment strategy introduced by Sangwan et al.2 In this
technique a small limbal biopsy is harvested from the healthy eye. The
biopsy is divided into minute explant pieces that are distributed over
human amniotic membrane (AM) and glued to the cornea (Figure 1). Out-
growth from individual explants merges with neighboring explant
growth.4 Reepithelialization is typically achieved within 2 weeks. This
review summarizes 404 cases in 31 clinical studies using SLET to date.
F IGURE 1 Illustration of 2-year outcomes following the use of simple limbal epithelial transplantation (SLET) for treatment of patients
with partial and total limbal stem cell deficiency (LSCD). A-J, Patients with partial LSCD following ocular burns: A-F, Preoperative
photographs and F-J, 2-year postoperative photographs showing a completely epithelized and stable corneal surface. K-U, Patients with
total LSCD: K-O, Preoperative clinical photographs. P-T, 2-year postoperative photographs after SLET using Slit-lamp photography. Images
reprinted from Basu et al3
Significance statement
The present review examines work reporting simple limbal
epithelial transplantation (SLET), an innovative technique
that uses minimal limbal tissue from the healthy eye to
regenerate the cornea in the limbal deficient diseased eye.
Results since the introduction of SLET in 2012 suggest that
the success rate is comparable to established techniques,
conjunctival-limbal autograft and cultured limbal epithelial
transplantation. However, SLET has the advantages of
requiring a smaller biopsy, achieving harvest and transplan-
tation in a single operation, and the unnecessity of cell cul-
ture laboratories. AlloSLET, a novel modification of SLET
using allogeneic tissue, promises to further improve out-
come through promotion of early resolution of inflammation
in the injured/diseased eye.
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2 | CURRENT OPTIONS FOR TREATMENT
OF LSCD
Reepithelialization of the corneal surface and improved visual acuity
are the primary and secondary aims in treating LSCD. Currently, there
are two main surgical techniques available using autologous limbal
tissue; conjunctival-limbal autograft (CLAU), and cultured limbal epi-
thelial transplantation (CLET). In the CLAU technique two
conjunctival-limbal biopsies are harvested (120 cornea circumference
each as described in the original CLAU technique) and transferred
directly to the affected limbal deficient eye.5 Thus, an advantage of
this procedure is that it does not require the use of a transplant sub-
strate, saving the expense of using AM. Published reviews summariz-
ing results of CLAU report a success rate of between 80% and 100%
and improvement in visual acuity of 25% and 100%, with a survival
rate of 62% at 6-year follow-up.6,7
The CLET technique depends on the culture of limbal biopsies to
produce limbal cell sheets prior to transplantation.8 The introduction
of the CLET procedure by Pellegrini et al. in 1997 offered a signifi-
cant advantage over CLAU by harvest of a smaller amount of limbal
tissue, minimizing the risk of iatrogenic injury to the healthy eye.8
Meta-analysis shows successful reepithelialization in 72% (n = 720)
of cases and improved visual acuity in 63% (n = 539) of cases
reporting the use of the standard CLET technique.9 This technique
has been criticized for use of mouse cells and other xenogeneic com-
ponents in preparation of the cultured sheets, potentially resulting in
infection and quality variation.10 However, it is possible to substitute
AM for mouse feeder cells.11,12 As evidence of its safety, in 2015,
the CLET technique advanced to become the first stem cell-based
therapy to receive approval for application throughout the European
Union (EU) under the trade name “Holoclar”.13
Several non-limbal cell types have also shown promise in treating
LSCD, offering options for treatment of bilateral LSCD using autolo-
gous cells and avoiding immunosuppression.14 Among alternatives,
the cultured oral mucosal epithelial transplantation (COMET) tech-
nique has been most widely reported.15 Use of this tissue allows
treatment of patients with Stevens-Johnson syndrome.16 The success
rate for COMET is comparable to CLET, resulting in reepithelialization
in 63% (n = 230) of reported cases and improved visual acuity in 68%
(n = 202).17
2.1 | Current challenges in treatment of LSCD
Though complications are rare and reepithelialization of the donor site
usually occurs, the risk associated with taking two large limbal biopsies
from the healthy donor eye is a concern associated with CLAU.18–20
The CLET and COMET techniques address this challenge but require
production of cultured sheets in a good manufacturing practice-
regulated laboratory, which is expensive and limits accessibility. The
COMET technique is promising, but peripheral neovascularization fol-
lowing surgery has been reported in many cases.16 The use of anti-
angiogenic agents in concert with COMET has shown benefit. However,
inhibition of vascular endothelial growth factor has been shown to
affect the overall wound healing response and induce corneal melt.21
SLET offers several advantages compared with the above options:
(a) risk of iatrogenic damage to the donor eye is reduced; (b) a small
biopsy means the procedure can be repeated if necessary; (c) SLET
does not require expensive specialized culture facilities; and (d) The
SLET procedure can be performed in one operation streamlining
patient care, resource management, and reducing costs. Results of a
recent study involving 125 patients show that SLET can be success-
fully used to treat partial and total LSCD (Figure 1).3
Treatment of bilateral LSCD remains a challenge. In addition to
COMET, conjunctival-limbal allografts from a living-related relative (lr-
CLAL) or cadaveric tissue (keratolimbal allograft [KLAL]) are options.
There have been two reports of modified SLET using allogeneic limbal
tissue (alloSLET) to treat bilateral LSCD. AlloSLET compared with lR-
CLAL and KLAL procedures have so far not been directly compared.
Regardless of the procedure, systemic immunosuppressants are criti-
cal for survival of allograft tissue.22,23 A standard of care and rec-
ommended duration of immunosuppressants necessary to prevent
allograft rejection has yet to be defined.22 Large studies reporting
KLAL and lr-CLAL procedures suggest an average duration of 4224-
4425 months, whereas the only large study reporting alloSLET for
bilateral LSCD recommends gradual reduction over 2 years followed
by the indefinite use of systemic and topical immunosuppressants.23
Patients should be monitored for adverse systemic effects while tak-
ing immunosuppressants, which may include hypertension, diabetes
mellitus, and biochemical abnormalities.22
3 | CHARACTERISTICS OF SLET STUDIES
The present review is based on a search of the National Library of
Medicine (PubMed) database using the term “simple limbal epithelial
transplantation” that gave a list of 31 publications reporting pre-
clinical results of SLET (Table S1) and one publication optimizing the
SLET technique.26
As of August 2019, 404 cases of SLET were reported. The eight
largest case series' reported treatment of 125,3 68,27 30,28 30,29 30,23
18,30 15,31 and 1132 eyes. These included the largest prospective
study to date, with 125 patients and a follow-up period of at least
1 year3 and a multicenter international study of 68 patients.27 The
remaining 23 studies were noncomparative single case studies or case
series of 10 eyes or less.2,4,33–52 One study directly compared SLET
with CLAU, with 10 patients randomly assigned to each group.33 The
Sangwan group in India published the most studies.2,3,27,29,35,42–49
Other centers in India,4,23,28,30–33,39–41,51,52 England,38 Brazil,36
Mexico,34 Thailand,50 and the United States37 also contributed.
4 | ETIOLOGY OF CASES TREATED
WITH SLET
Grading LSCD severity is important since some cases of partial LSCD
may not require stem cell transplant.53,54 SLET was mainly used in the
318 JACKSON ET AL.
treatment of adults and children with uniocular total and partial LSCD
resulting from burns and chemical injuries (Table S1). Patients with
unilateral LSCD and a clinically non-inflamed wet ocular surface are
ideal candidates for SLET3,37 Preliminary reports also indicate that
SLET has potential for use in non-LSCD ocular diseases; ocular surface
squamous neoplasia (OSSN) (9 eyes),35,41,51 laryngo-onycho-
cutaneous syndrome (1 eye),39 pterygium (9 eyes),34 and recurrent
pterygium (4 eyes) if results are confirmed in larger studies.55 How-
ever, pterygium can be treated using pterygium extended removal
followed by autologous extended conjunctival grafting, which has a
high success rate and is safe, simple, and fast to perform.56
It has been shown that SLET can be used in patients with LSCD
following failure of treatment with CLET.29 At a mean follow-up of
2.3 years, 80% of the 30 eyes treated by SLET maintained a success-
ful outcome without complications. Bilateral autoimmune diseases
such as Steven-Johnsons syndrome and ocular cicatricial pemphigoid
are contraindications for SLET using autologous tissue. A recent study
also showed that scleral ischemia resulting from chemical injury is a
poor prognostic indicator for success using SLET.31
SLET using biopsies of contralateral autologous tissue is most
common. Although larger studies are necessary before recommenda-
tions can be made, recent case studies show the use of alloSLET for
treatment of LSCD with a range of etiologies including extreme dry
eye,40 chemical injury,47 and iatrogenic LSCD induced by mitomycin
treatment for conjunctival melanoma.38 Iyer et al. also suggested inno-
vative use of alloSLET as an acute temporary biological bandage.30
The goal of this treatment was to provide immediate stabilization of
the wound environment, minimize more serious damage, and prepare
the wound for future SLET using autologous tissue.
5 | THE SLET TECHNIQUE
Most studies used the original autologous SLET technique described
by Sangwan et al. harvesting a small biopsy of limbal tissue from the
healthy eye.2 In summary, the injured eye is prepared with a 360 per-
itomy, and the vascular pannus covering the cornea is removed
(Figure S1). The eye is covered by AM to the extent of the peritomy,
secured with fibrin glue (Figure S1A). A small 2 × 2 mm biopsy (30
cornea circumference) is excised from the superior limbus of the
healthy eye and placed in a balanced salt solution (Figure S1B). The
limbal tissue biopsy is subsequently cut into tiny pieces that are fixed
onto the AM epithelial side up in a circular arrangement (avoiding the
visual axis) using fibrin glue (Figure S1C). A soft bandage contact lens
is then applied along with topical antibiotics and corticosteroids for
the first week or until healed (Figure S1D). A second layer of AM
instead of the contact lens can also be used.37,55 Use of
cryopreserved AM instead of fresh AM has been shown to be equally
effective and allows the use of this procedure in the United States.37
Partial LSCD can be treated using a modified SLET technique, where
superficial keratectomy is performed only in areas of fibrovascular
pannus, thus avoiding the intact limbus areas.3,28
The SLET procedure has also been used as a preventative measure
against development of LSCD. Wide excisional biopsies of ocular sur-
face squamous neoplasia and SLET can be performed in the same pro-
cedure to prevent LSCD after resection.35,41
When severe stromal opacification is present, patients will addition-
ally require penetrating keratoplasty (PK). It is sometimes necessary to
perform PK simultaneously with SLET if patients are unwilling to undergo
a second operation.27 Results from the three largest studies point to a
correlation of failure with simultaneous performance of PK with
SLET.3,27,28 Furthermore, SLET improves the corneal environment, which
may promote self-clearing of the stroma.3,28 Therefore, delaying PK for
at least a year post-SLET is recommended. In support of this, a large mul-
ticenter study reported an overall success rate of 84% (n = 68), but this
dropped to 20% in the eight eyes receiving simultaneous PK and SLET.27
However, the authors cautioned that the unsuccessful cases may have
presented with more serious etiology. Singh et al. described performance
of deep anterior lamellar keratoplasty in pediatric patients 9–15 months
post-SLET giving visual improvement of 64% (n = 11).32
Failure of SLET is correlated with regeneration of the cornea by
migrating conjunctival cells.50 Thus, in vivo confocal microscopy and
impression cytology can be useful in determining the phenotype of
regenerated epithelium on the cornea, allowing early diagnostic assess-
ment of failure and management before clinical symptoms appear.50
6 | MECHANISM OF REGENERATION
The success of SLET is in large part attributed to in vivo expansion of
transplanted explants on the corneal surface. However, the exact
mechanism in terms of the individual contribution of fibrin glue, AM,
limbal biopsy size, distribution of the biopsies, preexisting stem cells,
and migration pattern of transplanted cells is as yet unknown.
Detailed discussion of the role of these factors in reestablishing an
epithelialized cornea is beyond the scope of the present review. The
proposed benefits of the major components, fibrin glue and AM, and
the source of proliferating stem cells will be briefly discussed here.
Fibrin glue was first reported as a replacement for sutures in an
AM transplantation (AMT) procedure in 11 patients with partial
LSCD.57 Here, reepithelialization was achieved through growth from
residual limbal and corneal tissue, without the need to transplant
limbal cells. Kheirkhah and colleagues suggested that the glue forms a
full contact seal between the transplanted AM and the corneal sur-
face, ensuring reepithelialization occurs on the surface of the AM
rather than underneath, taking full advantage of the AM microenvi-
ronment.57 in vitro work has shown that fibrin glue inhibits cell migra-
tion, which in SLET may prevent ingrowth of conjunctival tissue at a
critical phase and promote expansion of epithelial cells from explants
on the AM surface.58 Growth rates vary between explants from the
same donor placed in the same eye, which may be attributed to the
amount of fibrin glue used for their individual attachment or to differ-
ences in handling during transplant.4 Fibrin glue has also been shown
to extend the beneficial effects of AM by delaying its breakdown
compared with sutures.7,57
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The main benefit of AM is in its early application to control inflam-
mation. It provides a substrate to promote the formation of a well-
differentiated stratified corneal epithelium.59 The advantage of the
addition of limbal tissue in SLET (compared with AM alone as used in
the AMT procedure) is highlighted where limbal explants have been
lost postoperatively, resulting in failure of SLET despite the presence
of AM.3 Amescua et al. used ultra-high-resolution optical coherence
tomography to reveal that the transplanted AM persisted at least
4 months post-SLET (in one patient).37
The relative contribution of transplanted cells and residual surviving
stem cells to the regenerated epithelium is unknown. A stable source of
proliferating stem cells is necessary to restore long-term homeostasis of
the corneal epithelium. These may be established through transplanted
stem cells becoming embedded or by dormant residual stem cells
becoming reactivated. It is possible that in some cases removal of
fibrotic tissue and paracrine signals from transplanted explants is suffi-
cient to stimulate residual stem cells to resume their homeostatic func-
tion. Preliminary investigation to resolve these questions has revealed
the presence of focal points of basal layer cells expressing putative
markers for stem cells (ΔNp63α and ABCG2) post-SLET3; the presence
of a mix of patient and donor cells on the cornea several months post-
alloSLET30; and patches of outgrowth emerging from individual
explants growing in a centripetal pattern that eventually merge with
outgrowth from neighboring explants.37 Although it is clear that the
role of transplanted cells needs further investigation in larger studies,
these initial analyses suggest that the rapid reepithelialization seen
post-SLET can be attributed, at least in part, to transplanted proliferat-
ing cells from limbal explants.
7 | RESULTS
Most studies used reversal of the main features of LSCD as the primary
measure of success. This is defined as complete reepithelialization, a
clinically stable corneal epithelium and reversal of vascularization.60
Improved visual acuity was used as a secondary definition of success.
Reported follow-up periods ranged from 6 to 59 months. Failure usually
occurred within 6 months of surgery (Table 1). Combined results show
that 83% (n = 336) of SLET operations were successful by the primary
criterion and visual acuity improved in 69% of cases (n = 258) (Table 1).
Summarizing results by severity, the success rates were 74.2% (n = 35)
for partial LSCD and 76.8% (n = 151) for total LSCD (Table 1).
The overall success rate compares well with other procedures that
use autologous limbal tissue.7,9,17 A direct comparison between SLET
and CLAU performed on patients with the same etiology and in the
same clinical setting supports SLET as an equally safe and effective
treatment for LSCD.33 A primary success rate of 62.5% (n = 30) was
also reported where SLET was performed in cases of failed CLET.29
The success rate declined in treatment of pediatric patients with
LSCD, with a rate of 71% compared with 85.5% in adults.3,28,52 Suc-
cessful treatment of pediatric LSCD using CLET has also been disap-
pointing (46.7%),61 suggesting pediatric LSCD is especially challenging.
This could be linked to the pressure for young patients to undergo
surgery earlier (before inflammation is fully controlled) in order to
reduce the risk of developing amblyopia (lazy eye),28 which often
accompanies sensory vision loss. Furthermore, ocular inflammation is
correlated with failure62 and children generally experience more
inflammation.63
Overall, SLET compares well with other procedures (CLAU, CLET,
COMET) that use autologous tissue for treatment of LSCD, resulting
in similar average primary and secondary criteria success rates. Impor-
tantly, SLET has now been validated in several larger studies and in
several international centers since the first published report in
2012.3,27–29 Many studies have reported long-term success, with
follow-up periods of 12 to 59 months (Tables 1 and 2).3,27,28,30,35,38,39
8 | RISK FACTORS FOR FAILURE AND
COMPLICATIONS
8.1 | Preoperative
The presenting features of the patient eye should be considered when
deciding treatment. Absolute contraindications include a dry ocular
surface, blind eye with no visual potential, disorganized anterior seg-
ment, and the continued presence of adnexal pathologies.23 Presenta-
tion with LSCD resulting from acid injury is also correlated with
failure.28 The association of presenting features with prognosis post-
SLET has been summarized in a review by Shanbhag et al. (see their
table 123).
Preexisting symblepharon is correlated with failure.3,27,28
According to Basu et al., the presence of symblepharon extending
toward the cornea pre-SLET could indicate conjunctival deficiency,
and outcomes may improve if symblepharon is addressed before or at
the time of SLET.3 A retrospective case series of four children where
only one patient had a completely successful outcome also noted that
recurrence of LSCD coincided with areas of severe preoperative sym-
blepharon.52 The three partial success patients had initially presented
with more severe injury and extensive LSCD. Thus, authors suggested
that damage to conjunctival stem cells may have contributed to fail-
ure. Repeat SLET combined with conjunctival autograft transplant
resulted in reepithelialization and an avascular surface.
Optimization of the ocular surface including fast resolution of
inflammation prior to SLET is important to give the best chance for
successful outcome, especially in pediatric cases.3,27,52 Glucocorti-
coids and AM transfer are often used to reduce inflammation in the
acute phase and induce epithelization. Iyer and colleagues have
shown that alloSLET can also be successfully used for this purpose.30
8.2 | Intraoperative
Based on poor results when combining PK with CLET, Basu and col-
leagues recommend identifying patients with thin corneas by optical
coherence tomography or ultrasound bio-microscopy before surgery
so that lamellar corneal graft can be performed simultaneously with
SLET if required.3,64
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The most common complications following SLET reported in the three
largest follow-up studies (involving 125,3 68,27 and 3028 patients)
were focal recurrence of LSCD,27 progressive conjunctivalization,3,28
progressive symblepharon,3 and keratitis (Table 1).3,27 More unusual
complications were loss of transplants following surgery,3 epithelial
defects that persisted for more than 6 months,29,36 and pyogenic
granuloma.3,27,34
One study reported corneal epithelial hyperplasia following SLET
in an 11-year-old boy.49 The authors suggested that in young patients
the contact lens should be removed as soon as possible after corneal
epithelialization is complete due to the high rate of cell proliferation
that is typically seen.
A trial of 30 patients who underwent SLET after failed CLET
reported zero cases of iatrogenic LSCD despite harvest of multiple
biopsies from donor eyes.29 Harmless subconjunctival hemorrhage
after biopsy harvest, which resolved within 1 month was noted in
28% of donor eyes in the largest study involving 125 patients.3 Iatro-
genic LSCD at the site of the donor limbus was also noted in one
patient.
In summary, preexisting symblepharon and simultaneous perfor-
mance of PK with SLET are the main features correlated with SLET
failure. Complications following SLET are relatively benign and man-
ageable. The risk of iatrogenic LSCD at the donor site is also low even
after harvest of multiple biopsies for repeat SLET.
9 | ALLOGENIC SLET
Very little has been published on the use of alloSLET for permanent
restoration of the cornea for treatment of bilateral LSCD. Bilateral
LSCD often occurs secondary to Stevens-Johnson syndrome, mucous
membrane phemigoid (MMP), and severe chemical burns, which pro-
duce extensive cicatrization or dryness making patients unsuitable
candidates for treatment with SLET.23 A total of 56 eyes in six sepa-
rate studies have used alloSLET.23,30,38,40,47,50 Immunosuppressant
steroids were prescribed topically (19 eyes30,38), systemically
(1 eye47), or in combination (30 eyes23). Transplant rejection can be
managed by increasing the dose of systemic and topical immunosup-
pressants.23,47 A total of 30 eyes were treated in the largest alloSLET
study reported so far; 16 eyes received living-related donor tissue and
14 eyes of 13 patients received cadaveric donor tissue.23 At the final
follow-up (median 28 months), the overall improvement in visual acu-
ity was from hand-motion to 20/60 in more than 60% of eyes.
Achievement of a stable corneal surface indicating successful out-
come varied slightly between the two groups with success noted in
14 of 16 (87.5%) eyes receiving living-related SLET and in 11 of
14 (78.6%) eyes in the cadaveric group at the final follow-up (average
28 months). No serious systemic complications were noted. These
results compare well with typical results using lr-CLAL and KLAL tech-
niques, for example, in a large retrospective case series 105 of
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Iyer et al. investigated the effectiveness of alloSLET in manage-
ment of acute inflammation in 17 patients (18 eyes) with severe grade
4 or worse chemical injury (Dua's classification).30 Ten of the patients
were children with an age range of 3 months to 10 years. Systemic
immunosuppressants were not used since later rejection of allogenic
transplants was expected. Follow-up ranged from 3 to 23 months.
The authors performed alloSLET with the intention of aiding fast epi-
thelialization of the denuded cornea and to promote early reconstruc-
tion of the corneal surface and not with an aim toward long-term
survival of the allogenic cells (Figure S2). They speculated that the
small size of the allogenic explants may have reduced the antigenic
load leading to slow rejection. Complete reepithelialization was
achieved within 10-40 days in 17 of 18 (94%) eyes. Improved visual
acuity was seen in 13 of 17 (76%) patients. Symblepharon involving
one or two quadrants was noted in three eyes.
Iyer and colleagues hypothesize that early resolution of inflamma-
tion facilitated by the use of AM and topical steroids may have been
influential in preventing further damage to residual stem cells.30 Fur-
thermore, early reepithelialization by allogenic explants may have also
reduced ocular surface inflammation allowing residual stem cells to
repopulate the cornea.
Though studies are so far limited, reports suggest that use of AM
in the alloSLET procedure and regeneration of an epithelial layer using
allogenic explants quietens inflammation on the ocular surface. There-
fore, in addition to offering an alternative treatment for bilateral
LSCD, alloSLET may be especially applicable for fast temporary treat-
ment of pediatric patients, where inflammation has been reported as a
key factor hindering successful outcome. AlloSLET offers the advan-
tage of quickly restoring a clear epithelial layer, albeit of a temporary
nature, which aids in improvement in visual acuity as early as a month
following injury.30 Thus, the risk of amblyopia can be reduced or
addressed earlier in pediatric patients. Importantly, the use of alloge-
neic tissue as a temporary application maintains an undisturbed
healthy alternate eye. Valuable autologous limbal tissue can then later
be harvested for use in SLET once inflammation in the injured eye has
subsided, giving a higher chance of success.
10 | FUTURE STUDIES
The AM carrier could be a critical factor to the success of SLET. It con-
tains anti-inflammatory cytokines, growth factors, and provides a sub-
strate that may allow stem cells in SLET explants to embed. SLET
results may be further improved with the use of cross-linked AM.65
Comparison of the effect of using denuded vs. intact AM would also
be useful. Consideration of a standardized synthetic replacement for
AM could also be evaluated to eliminate the inherent variability found
in AM, a natural tissue.
Cumulative results show that although regeneration of the corneal
epithelium occurs in 83.5% of SLET operations, visual acuity is
improved in only 68.7% of patients (Table 1). Avenues for improve-
ment include the pursuit of work indicating that inflammation plays a
key role in SLET operations with poor outcomes.3 Inflammatory state
may be influenced by the time between injury and operation, as
reported in several studies.3,28,62 To advance the treatment of LSCD
in children, it may be necessary to focus on faster resolution of inflam-
mation before SLET.28 Temporary application of alloSLET may accom-
plish this, and larger studies are needed to confirm.30
Mittal et al. showed that individual explants from the same donor
often vary in outgrowth.4 Follow-up studies could optimize the
amount of fibrin glue used for mounting explants, as well as limbal
explant size, orientation, harvest site, and handling techniques.
Although SLET minimizes the amount of biopsy harvested from
the donor eye, the same technique using an alternative source of
autologous tissue may have the additional benefit of offering treat-
ment of bilateral LSCD. Oral mucosal tissue has proved effective
in treating LSCD transplanted as cultured sheet transplants
(COMET).15,66 Transfer of small oral mucosal biopsies in a simple oral
mucosal epithelial transplantation (SOMET) technique would avoid
the need to harvest ocular limbal material altogether.
Direct comparison of the effectiveness of CLAU, CLET, and SLET
in a large randomized prospective study would be useful.
11 | CONCLUSION
In conclusion, results so far indicate that SLET offers a comparable
alternative to CLAU and CLET using the two main criteria for success:
corneal re-epithelialization and improvement in visual acuity. In addi-
tion, there are advantages to harvesting a smaller biopsy for trans-
plant, such as lowered risk of iatrogenic LSCD and the option for
repeat operations. Importantly, harvest and transplantation are
accomplished in a single operation, which increases efficiency, pro-
motes accessibility, and reduces cost. Latest work shows limbal allo-
grafts can be used successfully in treatment of bilateral LSCD.
Direct transfer of limbal explants may support superior mainte-
nance of stem cell phenotype and function following transplant. On
the other hand, analysis of biopsies used for CLET transplants has
shown a correlation between clinical success and stem cell content
suggesting stem cells are maintained during culture.67 The opportu-
nity for gene editing prior to transplantation may also be an important
advantage of the CLET technique.
Long-term follow-up studies equivalent to CLAU and CLET are
now becoming available, and results using SLET are promising.
AlloSLET used as a temporary treatment to resolve initial inflamma-
tion and quickly recover an intact epithelial layer also holds great
potential. This may be especially important in treating pediatric cases
of LSCD. Avenues for improvement should be further explored,
including the feasibility of using non-limbal autologous tissue from the
oral cavity for treatment of bilateral LSCD (SOMET).
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